Trevena, Inc.

219 articles with Trevena, Inc.

• Trevena Announces NIH Has Resumed Recruiting Patients in Proof-of-Concept Study for TRV734 in Opioid Use Disorder

  6/16/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that NIDA has resumed recruiting patients for its proof-of-concept study for TRV734, the Company’s novel mu-opioid receptor selective agonist.

• Trevena to Present at the JMP Securities Life Sciences Conference

  6/9/2021

  Trevena, Inc. announced that Carrie Bourdow, President and Chief Executive Officer of Trevena, Inc. will participate in a fireside chat at the JMP Securities Life Sciences Conference being held virtually June 16 - 17, 2021.

• Trevena Announces Presentations of OLINVYK® Health Economic Models at ISPOR 2021

  5/19/2021

  Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the International Society for Pharmacoeconomics and Outcomes Research

• Trevena Announces Presentation of OLINVYK® Respiratory Safety Data in High-Risk Patients at the 46th Annual ASRA Meeting

  5/12/2021

  Elderly and obese patients receiving OLINVYK are not at increased risk for respiratory depression, compared to younger and non-obese patients, based on exploratory analysis

• Trevena Announces TRV027 Selected by NIH-Funded ACTIV Initiative For COVID-19 Trial

  5/6/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that TRV027, the Company’s novel AT1 receptor selective agonist, has been selected for an NIH ACTIV trial in COVID-19 patients.

• Trevena to Release First Quarter 2021 Financial Results on May 6, 2021Company to host conference call on May 6, 2021, at 8:00 a.m. ET

  5/5/2021

  Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will release its financial results for the first quarter ended March 31, 2021, prior to the market open on Thursday, May 6, 2021. Company management will host a conference call and webcast to discuss its financial results

• Trevena, Inc. to Participate at the Sachs Associates 4th Annual Neuroscience Innovation Forum

  4/29/2021

  Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that Mark A. Demitrack, M.D., Senior Vice President and Chief Medical Officer, will be participating at the 4th Annual Sachs Associates Neuroscience Innovation Forum taking place from Wednesday, April 28 to Friday, April 30, 2021.

• Trevena Announces TRV027 Selected for Study in Global REMAP-CAP Trial in COVID-19 Patients

  4/21/2021

  -- REMAP-CAP is led by experts in pandemic response and builds upon a worldwide clinical trial network evaluating treatments for COVID-19 Interim review of Imperial College London TRV027 study data supports transition to larger study

• Trevena, Inc. Announces Presentations of OLINVYK™ Health Economic Models at AMCP 2021 Annual Meeting

  4/15/2021

  Trevena, Inc. (Nasdaq: TRVN) , a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced two poster presentations at the AMCP 2021 Annual Meeting.

• Trevena, Inc. Reports Fourth Quarter and Full Year 2020 Results

  3/9/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, reported its financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of its 2020 and 2021 year-to-date operational highlights.

• Trevena to Release Fourth Quarter and Full Year 2020 Financial Results on March 9, 2021

  3/5/2021

  Trevena to host conference call on March 9 th , 2021, at 8:00 a.m. ET --

• Trevena, Inc. to Participate in March 2021 Virtual Investor Conferences

  3/1/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in two upcoming virtual investor conferences in March.

• Trevena, Inc. to Present at the 10th Annual SVB Leerink Global Healthcare Conference

  2/22/2021

  Trevena, Inc. (TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced that it will present a corporate update at the 10 th Annual SVB Leerink Global Healthcare Conference on Friday, February 26, 2021 at 8:40 a.m. EST.

• Trevena, Inc. Announces Publication Highlighting OLINVYK™ Respiratory Safety Data in High-Risk Patients in Pain & Therapy

  1/28/2021

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced the publication of a new analysis of respiratory safety data from the OLINVYK Phase 3 multi-site “real world” safety study in Pain and Therapy.

• Trevena, Inc. to Participate in Two Upcoming Virtual Investor Conferences

  1/7/2021

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in two upcoming virtual investor conferences, with additional details below.

• Trevena, Inc. Announces Publication Highlighting GI Tolerability Profile of OLINVYK™ (oliceridine) injection in Pain and Therapy

  11/20/2020

  Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system (CNS) disorders, today announced a publication, titled “Oliceridine is Associated with Reduced Risk of Vomiting and Need for Rescue Antiemetics Compared to Morphine: Exploratory Analysis from Two Phase 3 Randomized Placebo and Active Controlled Trials,” with lead author Tim Beard,

• Trevena, Inc. to Participate in the Following November Virtual 2020 Investor Conferences

  11/9/2020

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in the following conferences in the month of November and invites investors to participate by webcast.

• Trevena, Inc. Announces Three OLINVYK™ Presentations at the Virtual American Society of Anesthesiologists 2020 Annual Meeting

  10/5/2020

  Posters highlight improvements in respiratory safety and gastrointestinal tolerability associated with OLINVYK (oliceridine) injection vs. IV morphine

• Trevena, Inc. Announces Presentations at the Virtual 2020 American College of Clinical Pharmacology Annual Meeting

  9/21/2020

  Live presentation highlightingTRV027 as a potential treatment for COVID-19 acute respiratory distress syndrome (ARDS) / abnormal clotting

• Trevena, Inc. to Present at September 2020 Virtual Investor Conferences

  9/2/2020

  Trevena, Inc., a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with central nervous system disorders, announced that management will participate in the following conferences in the month of September and invites investors to participate by webcast.